menu
    • menu
    [{"orgOrder":0,"company":"Landos Biopharma","sponsor":"LianBio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0.22,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.22,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ LianBio","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ LianBio"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"LABP-104","moa":"LANCL2","graph1":"Immunology","graph2":"Phase I","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Landos Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Landos Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Landos Biopharma \/ Icahn School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NX-13","moa":"NLRX1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Landos Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"NX-13","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"NX-13","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Landos Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"NImmune Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Omilancor","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ NImmune Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ NImmune Biopharma"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"KU Leuven","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"NX-13","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ KU Leuven","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ KU Leuven"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"NX-13","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.20999999999999999,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ Abbvie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Abbvie Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Landos Biopharma

    Menu

    Landos Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NX-13

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : $212.5 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            AbbVie To Acquire Landos Biopharma, Strengthening Portfolio in Inflammatory Diseases

                            Details : AbbVie will advance Landos’ lead investigational asset NX-13, a first-in-class, oral NLRX1 agonist with a bimodal mechanism of action, which is anti-inflammatory and facilitates epithelial repair.

                            Brand Name : NX-13

                            Molecule Type : Small molecule

                            Upfront Cash : $137.5 million

                            March 25, 2024

                            Lead Product(s) : NX-13

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : $212.5 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NX-13

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : KU Leuven

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to ...

                            Details : The collaboration aims to investigate the effects of NX-13, first-in-class, oral, gut-selective, NLRX1 agonist, on epithelial cells with the Inflammatory Bowel Disease.

                            Brand Name : NX-13

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 14, 2023

                            Lead Product(s) : NX-13

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : KU Leuven

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omilancor

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : NImmune Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Josep Bassaganya-Riera Launches NImmune Biopharma with Phase 3-Ready Clinical Candidate Omilancor for the Trea...

                            Details : BT-11 (omilancor) is a novel, oral, gut-restricted therapeutic targeting the lanthionine synthetase C-like 2 (LANCL2) pathway which decreases the production of key inflammatory mediators causing ulcerative colitis.

                            Brand Name : BT-11

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 22, 2023

                            Lead Product(s) : Omilancor

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : NImmune Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NX-13

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual...

                            Details : NX-13 is a first-in-class novel, gut-selective oral therapeutic candidate that targets NLRX1 that has been associated with the modulation of inflammatory cytokines for UC and CD.

                            Brand Name : NX-13

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 11, 2023

                            Lead Product(s) : NX-13

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NX-13

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $16.7 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Landos Biopharma Announces $16.7 Million Private Placement Financing

                            Details : Landos Biopharma anticipates using the net proceeds from the investment to advance the development of NX-13 for Ulcerative Colitis and Crohn’s Disease and for other general corporate purposes.

                            Brand Name : NX-13

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 05, 2023

                            Lead Product(s) : NX-13

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $16.7 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NX-13

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial

                            Details : NX-13 is a novel, gut-restricted, orally active, small molecule therapeutic candidate for the treatment of UC. NX-13 targets NLRX1, a mitochondria-associated receptor with the ability to modulate immune responses.

                            Brand Name : NX-13

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 03, 2022

                            Lead Product(s) : NX-13

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omilancor

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Icahn School of Medicine

                            Deal Size : $3.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohn’s Disease with the Icahn School of ...

                            Details : Landos Biopharma collaborate with Icahn School of Medicine to conduct a Phase 2 trial of omilancor, a novel, oral, gut-restricted, small-molecule investigational drug that targets the Lanthionine Synthetase C-Like 2 (LANCL2) pathway impacting the gastroi...

                            Brand Name : BT-11

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 20, 2021

                            Lead Product(s) : Omilancor

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Icahn School of Medicine

                            Deal Size : $3.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LABP-104

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Landos Biopharma to Present Results of LABP-104 in Lupus at the American College of Rheumatology Convergence 2...

                            Details : Oral treatment with LABP-104 in preclinical models of Systemic Lupus Erythematosus (SLE) resulted in enhanced Treg function, decreased kidney inflammation and reduced interferon gamma signaling.

                            Brand Name : LABP-104

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 15, 2021

                            Lead Product(s) : LABP-104

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omilancor

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Landos Phase 2 Data of Omilancor in Ulcerative Colitisr Oral Presentation

                            Details : Discovered using Landos proprietary LANCE® Advanced A.I. platform, omilancor is a novel, oral, gut-restricted small molecule investigational drug that targets the Lanthionine Synthetase C-Like 2 (LANCL2) pathway impacting the gastrointestinal tract.

                            Brand Name : BT-11

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 22, 2021

                            Lead Product(s) : Omilancor

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Landos Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omilancor

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : LianBio

                            Deal Size : $218.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement for Omilancor and NX-13

                            Details : LianBio will receive exclusive rights to develop and commercialize BT-11 and NX-13 in Greater China, South Korea, Singapore, Thailand, Vietnam, Myanmar, Cambodia, Indonesia, and the Philippines.

                            Brand Name : BT-11

                            Molecule Type : Small molecule

                            Upfront Cash : $18.0 million

                            May 17, 2021

                            Lead Product(s) : Omilancor

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : LianBio

                            Deal Size : $218.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth